Discovering a new role for the atrial natriuretic peptide: A novel risk factor for cardiovascular diseases
Abstract
Overview
Atrial natriuretic peptide, a diuretic, natriuretic and vasorelaxant hormone, is also
involved in the regulation of cardiovascular remodeling and it has been recently shown to be significantly
associated with higher occurrence of cardiovascular diseases. In fact, high plasma
ANP levels predict higher mortality rate for cardiovascular events. Moreover, ANP gene alterations
are associated with higher risk of cardiovascular intermediate phenotypes, such as left
ventricular hypertrophy, and of cardiovascular diseases, such as stroke and hypertension.
Thus, the characterization of ANP plasma levels, and of ANP genotype for known mutations can
be proposed as an informative component of the individual cardiovascular risk profile. (Heart International
2006; 2: 78-81)
Keywords
Atrial natriuretic peptide, Cardiovascular risk, Genetic
Article Information
Correspondence
Speranza Rubattu, MD, IRCCS Neuromed, Località Camerelle-Zona Industriale, 86077 Pozzilli (IS) – Italy, rubattu.speranza@neuromed.it
Further Resources
Trending Topic
Cardiovascular care continues to evolve in response to increasingly complex clinical realities, where advances in intervention, electrophysiology and population health must be integrated with a more critical appraisal of long-held assumptions. Across disciplines, there is a growing recognition that improving outcomes depends not only on technological progress, but also on refining our understanding of mechanisms, […]
Cardiovascular care continues to evolve in response to increasingly complex clinical realities, where advances in intervention, electrophysiology and population health must be integrated with a more critical appraisal of long-held assumptions. Across disciplines, there is a growing recognition that improving ...
Hypertension is the leading modifiable risk factor for global cardiovascular disease, responsible for an estimated 10.8 million deaths and more than 200 million disability-adjusted life years annually.1Â Despite the availability of effective pharmacological and lifestyle interventions, prevalence continues to rise, particularly in ...
Hypertension affects over 1.4 billion adults worldwide and remains the leading modifiable risk factor for global cardiovascular (CV) morbidity and mortality. It is responsible for an estimated 10.8 million deaths annually and contributes significantly to the global burden of ischaemic heart disease, ...
Hypertension has been associated with increased cardiovascular morbidity and mortality, as well as with overall elevated all-cause mortality.1 Prevalence increases with age, affecting 28.5% of US individuals aged 20–44 years, 58.6% of those aged 45–64 years and 76.5% of those aged 65 years and older.2 In ...
Hypertension (HTN) is one of the largest contributors to cardiovascular (CV) morbidity and mortality in the USA and is estimated to affect 47% of the adult population or approximately 122 million adults older than 20 years of age.1Â Recent estimates suggest that over 40% ...
Atrial fibrillation (AF) is one of the most common arrhythmias. It affected 33.5 million people worldwide in 2010, a number that is expected to double by 2050.1Â AF prevalence increases with age, and approximately 25% of individuals aged 40 years or older will develop AF ...
Hypertension is a global health problem, with an estimated 1.13 billion individuals affected.1 Patients with hypertension, especially when resistant to conventional therapy, are at high risk of sequelae, e.g., ischaemic heart disease, haemorrhagic and ischaemic stroke, cardiac failure, peripheral vascular ...
...
...
...
...
...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
